Treatment of Androgenetic Alopecia in Men for 24 Weeks

Status Active, not recruiting

Clinical Trial Summary

A prospective, randomized, double-blind, single-center, placebo-Controlled, parallel-group study to evaluate the efficacy and safety of a new pharmaceutical form Minoxidil 5% in men after 24 weeks of treatment. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

Clinical Trial Description

Participants will be randomized at a 2: 1 ratio to receive new pharmaceutical form Minoxidil 5% and placebo, respectively. Through this method, it is possible to obtain more information about the effectiveness of investigational product. The primary objective of the MINOX study is to demonstrate the superiority of a new topical 5% pharmaceutical form of minoxidil (experimental drug) in treating men with androgenetic alopecia (Hamilton-Norwood scale IIIv, IV or V) compared to placebo when administered for 180 days. Secondary objectives: 1- To evaluate the efficacy of a new topical 5% minoxidil pharmaceutical form in the treatment of men with androgenetic alopecia, compared to placebo, by means of terminal strand density in the target area, evaluated 30 (±3), 60(±3), 90(±3) and 135(±3) days after the beginning of treatment. 2- To evaluate the efficacy of a new topical 5% pharmaceutical form of minoxidil in the treatment of men with androgenetic alopecia, compared to placebo, by means of the percentage of anagen strands in the target area, evaluated 30(±3), 60(±3), 90(±3), 135(±3) and 180(±3) days after the start of treatment. 3- Evaluate the efficacy of a new topical 5% pharmaceutical form of minoxidil in the treatment of men with androgenetic alopecia, compared to placebo, by means of the average length of hair strands in the target area, evaluated 30(±3), 60(±3), 90(±3), 135(±3) and 180(±3) days after the start of treatment. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04721548
Study type	Interventional
Source	Eurofarma Laboratorios S.A.
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	March 2, 2023
Completion date	September 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04953416` - Fractional Non-ablative Laser for the Treatment of Hair Loss	N/A
Completed	`NCT01929330` - Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers	Phase 1
Recruiting	`NCT05213936` - Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color	N/A
Completed	`NCT02919735` - Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)	Phase 2
Recruiting	`NCT02591823` - Hair Fall in Patients on Low Dose Methotrexate	N/A
Enrolling by invitation	`NCT01651689` - Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia	N/A
Completed	`NCT01189279` - Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia	Phase 1
Recruiting	`NCT01111981` - Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia	Phase 4
Terminated	`NCT01385839` - Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata	N/A
Active, not recruiting	`NCT03382184` - Fractional Photothermolysis for Hair Follicle Induction	Early Phase 1
Not yet recruiting	`NCT05544448` - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases	N/A
Completed	`NCT03689452` - The Effect of Platelet Rich Plasma on Non-scarring Alopecia	N/A
Completed	`NCT06409650` - To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia	Phase 2
Recruiting	`NCT00801086` - Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain	Phase 2
Completed	`NCT06095739` - Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002	N/A
Completed	`NCT05587699` - The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A	Phase 1
Completed	`NCT03351322` - ENERGI-F701 for Female Hair Loss Treatment	Phase 2
Not yet recruiting	`NCT01557491` - Hair Regrowth After Bicoronal Incision	N/A
Terminated	`NCT02935569` - Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy	N/A
Completed	`NCT01590238` - Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Treatment of Androgenetic Alopecia in Men for 24 Weeks — MINOX

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms